 SEATTLE, Nov. 23, 2020 GLOBE NEWSWIRE -- Adaptive Biotechnologies Corporation Nasdaq: ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 35 abstracts studying the use of Adaptives clonoSEQ Assay for minimal residual disease MRD assessment at the American Society of Hematology ASH virtual 62nd Annual Meeting and Exposition, December 5-8. clonoSEQ is the first and only U.S. Food and Drug Administration FDA-cleared assay for MRD assessment in chronic lymphocytic leukemia CLL, multiple myeloma and B-cell acute lymphoblastic leukemia B-ALL and is widely available to clinicians and patients across the U.S. 